Use of Monoclonal Antibodies (Casirivimab + Imdevimab) for Post-Exposure Prophylaxis and the Use of Sotrovimab for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

The objective of the project is to Minimize and/or eliminate the number of adults and pediatric patients with mild to moderate COVID-19 (confirmed by positive results of direct SARS-CoV-2 viral testing) who are 12 years of age and older weighing at least 40 kg, who are at high risk for progressing to severe COVID-19 and/ or hospitalization.